Medpace (NASDAQ:MEDP) Reaches New 52-Week High on Better-Than-Expected Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) shares hit a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $677.90 and last traded at $620.5350, with a volume of 153020 shares trading hands. The stock had previously closed at $528.12.

The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MEDP shares. Mizuho raised their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, BMO Capital Markets boosted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $560.92.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Ausbil Investment Management Ltd boosted its position in shares of Medpace by 5.5% during the second quarter. Ausbil Investment Management Ltd now owns 4,275 shares of the company’s stock valued at $2,324,000 after buying an additional 221 shares during the last quarter. Handelsbanken Fonder AB raised its position in Medpace by 0.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock valued at $3,718,000 after buying an additional 40 shares during the last quarter. Allied Private Wealth LLC bought a new position in Medpace during the 2nd quarter valued at $31,000. Polianta Ltd lifted its stake in Medpace by 21.4% during the 2nd quarter. Polianta Ltd now owns 3,400 shares of the company’s stock valued at $1,800,000 after acquiring an additional 600 shares in the last quarter. Finally, 180 Wealth Advisors LLC purchased a new position in Medpace during the 2nd quarter worth $201,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.7%

The stock has a market capitalization of $17.18 billion, a PE ratio of 35.25, a P/E/G ratio of 2.96 and a beta of 1.15. The stock’s fifty day simple moving average is $492.09 and its 200-day simple moving average is $494.49.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.